Therapeutic effect of cevimeline on dry eye in patient with jögrenʹ yndrome: a randomized, double-blind clinical tudy

Purpoe jögrenʹ yndrome () i a ytemic autoimmune dieae characterized by alivary and lacrimal glandular detruction leading to ymptom of dry mouth and dry eye. Dryne can alo occur in the abence of glandular detruction. Patient with have autoantibodie that bind to mucarinic acetylcholine receptor in the exocrine gland. Recently, a mucarinic acetylcholine receptor agonit, cevimeline, ha been approved for ue againt ymptom of dry mouth in patient with . In thi tudy, the efficacy of cevimeline in improving ymptom of dry eye wa examined. Deign Propective, randomized, double-blind, multi-center clinical tudy. Method ixty patient were randomly aigned to three group—placebo; cevimeline, 20 mg three time daily; or cevimeline, 30 mg three time daily—and received treatment for 4 week. Patient were evaluated before treatment, at week 2, at the end of treatment, and at the end of a 2- to 4-week follow-up period. Reult Compared with the placebo, tatitically ignificant difference were een with cevimeline, 20 mg three time daily, in ubjective ymptom, tear dynamic, condition of the corneoconjunctival epithelium, and global improvement rating. No difference wa found among the three group regarding the afe ue of the drug. Concluion Thee reult indicate that cevimeline, 20 mg three time daily, i afe and effective in improving ymptom of dry eye in patient with . Additional tudie, with larger patient population, are needed to further ae the effectivene of cevimeline for dry eye.